Coronary artery disease, atrial fibrillation Circulatory System
Conditions
Interventions
All patients will be contacted once in the follow-up period. Adverse events for both bleeding and thromboembolic reasons will be analysed (death, myocardial infarction, stent thrombosis, stroke, major
Sponsors
University Hospital Münster
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with coronary artery disease 2. Treated with drug-eluting stent implantation at Münster University Hospital 3. Indication for oral anticoagulation due to atrial fibrillation 4. Age > 18 years
Exclusion criteria
Exclusion criteria: 1. Age < 18 years 2. Current pregnancy 3. Underlying malignant disease 4. Previous stent thrombosis 5. Active bleeding 6. Other OAC indications than atrial fibrillation (e.g. pulmonary embolism, mechanical valves) 7. Patients who were unable to give informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Safety of triple therapy, measured using a standardized questionnaire at a single follow-up timepoint 2. Efficacy of triple therapy, measured using a standardized questionnaire at a single follow-up timepoint | — |
Secondary
| Measure | Time frame |
|---|---|
| Risk factors for events (bleeding or thrombotic), measured using a standardized questionnaire at a single follow-up timepoint | — |
Countries
Germany
Outcome results
None listed